Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
about
Acute lymphoblastic leukaemiaTreating childhood acute lymphoblastic leukemia without cranial irradiationA PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupOsteonecrosis in children with acute lymphoblastic leukemiaOutcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialCentral nervous system prophylaxis in diffuse large B-cell lymphoma.Chemotherapy-related side effects in childhood acute lymphoblastic leukemia in Indonesia: parental perceptions.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407Central nervous system disease in hematologic malignancies: historical perspective and practical applications.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trialCurrent concepts in the diagnosis and management of cytokine release syndrome.Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatmentDexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.Isolated central nervous system relapse of acute lymphoblastic leukemiaAuxological changes in UK survivors of childhood acute lymphoblastic leukaemia treated without cranial irradiation.Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.Treatment of pediatric acute lymphoblastic leukemia.Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.Glucocorticoid use in acute lymphoblastic leukaemiaAntimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Clinical trials in paediatric haematology-oncology: are future successes threatened by the EU directive on the conduct of clinical trials?Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.Childhood acute lymphoblastic leukaemia and relapse.Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutWhat determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesThrombosis and acute lymphoblastic leukaemia.Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
P2860
Q24602387-5BEF56A4-CFB1-4E45-804E-310DEC116ECEQ24644599-6B46044D-850A-4707-A243-991275687A5EQ24656610-3B6A8990-7EDE-46B1-B8E9-AEDF012EF333Q28066799-808DC222-DDEF-45AF-8698-028EC62A7571Q28543517-35D8F8A5-DC0F-4E1E-A214-B193A1D2DB75Q30251550-40D1C73B-1699-4DD1-BE3D-1DF856DB9685Q33499635-606FFFF1-F0B5-4575-8F4A-6A5A479A6DDCQ33557148-4F4E077B-97A0-41FB-82E1-5E597F642D21Q33559419-8CD50DBE-CD12-4107-9045-0727312CF817Q33585849-C74878D1-9F4C-42EC-A9FD-4615A617B8BFQ33637143-BD28E870-8DC2-4959-9974-98C3BB29BF60Q33647130-D4F93590-D10B-4869-BB81-240ED09A08B9Q33647139-DD43317A-E45C-48D9-AE69-B90B140A55A2Q33828580-6A3D5993-4C65-43E9-AC07-722B818F5F8BQ33886879-6CE35C73-E400-4CD8-BCD4-67BAF043CB55Q33997207-2F5770C3-AF25-439C-867C-A57221C2D827Q34003323-026D5798-BFC3-434D-BFF2-3316AD5890ABQ34038283-A197D318-1A44-4B01-91D7-6C035C332767Q34095614-D516E2CF-FA62-4861-91E1-71F8CC16E3DCQ34358853-E140E5F9-5167-4D73-A9F5-E32AE18A36F1Q34455093-25EDF8D7-F001-425D-B637-D5F8D50F94ADQ34509402-8F089C63-535F-41B5-9B4F-77C0714AF962Q34621846-00DF57E5-8844-4923-838C-A3CFCEFB5AD0Q35076156-0ACB38EA-1E15-40F0-AEA1-0E927183AD32Q35112206-0D925CDE-D2EC-4E64-98E2-5CF9139BFA39Q35196702-2D45AFD9-241A-4E86-B68F-97354B144F0AQ35781265-9F8AFBE8-6511-4A1D-AF93-16C124B785B9Q35844745-0F0AD471-3539-48EA-A387-58D4F1A22967Q35925012-60F1B06E-EEF3-4B4F-9EDB-BCFB19521565Q36155005-57196A2D-0F7A-42B2-92CF-F80800038492Q36261095-8B2D2E44-36DA-4B33-98F5-280D969796F5Q36287682-C7A4BDEB-9239-4AB4-A4E2-40D38B680C37Q36340652-F26907B0-9B49-49A0-91EC-595C1195F5E2Q36532537-B077C19F-D5C0-4277-A26F-45BFE0ABD215Q36678136-F246CC15-5DC1-44B5-B898-B80AE70BABDDQ36843677-015A70B4-D790-42F1-8A9A-7C4C18794294Q36869374-4699409B-3006-4C0E-9664-67C3DA7ECC44Q36895136-552898F6-D330-4F8B-A39C-EDAD5F7C55E6Q36988021-E5A7F07F-E4DF-4406-9006-8096ACACB190Q37078647-9236E1B5-80E1-4FD1-B8CC-8AB6C4AA8419
P2860
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@en
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@nl
type
label
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@en
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@nl
prefLabel
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@en
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@nl
P2093
P2860
P1476
Benefit of dexamethasone compa ...... ouncil ALL97 randomized trial.
@en
P2093
C D Mitchell
J Lilleyman
Medical Research Council Childhood Leukaemia Working Party
S E Kinsey
S M Richards
T O B Eden
P2860
P304
P356
10.1111/J.1365-2141.2005.05509.X
P407
P577
2005-06-01T00:00:00Z